Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials.

Lanini S, Ioannidis JPA, Vairo F, Pletschette M, Portella G, Di Bari V, Mammone A, Pisapia R, Merler S, Nguhuni B, Langer M, Di Caro A, Edwards SJL, Petrosillo N, Zumla A, Ippolito G.

Lancet Infect Dis. 2019 Aug 23. pii: S1473-3099(19)30284-1. doi: 10.1016/S1473-3099(19)30284-1. [Epub ahead of print] Review.

PMID:
31451421
2.

Criteria for discharge of patients with Ebola virus diseases in high-income countries.

Bevilacqua N, Nicastri E, Chinello P, Puro V, Petrosillo N, Di Caro A, Capobianchi MR, Lanini S, Vairo F, Pletschette M, Zumla A, Ippolito G; INMI Ebola Team.

Lancet Glob Health. 2015 Dec;3(12):e739-40. No abstract available. Erratum in: Lancet Glob Health. 2016 Jan;4(1):e27.

3.

Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?

Lanini S, Zumla A, Ioannidis JP, Di Caro A, Krishna S, Gostin L, Girardi E, Pletschette M, Strada G, Baritussio A, Portella G, Apolone G, Cavuto S, Satolli R, Kremsner P, Vairo F, Ippolito G.

Lancet Infect Dis. 2015 Jun;15(6):738-45. doi: 10.1016/S1473-3099(15)70106-4. Epub 2015 Apr 14. Review.

PMID:
25881871
4.

Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts.

Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, Bates M, Colagiuri R, Zijenah L, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Abubakar I, Hasan R, Zafar A, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 May;13(5):436-48. doi: 10.1016/S1473-3099(13)70015-X. Epub 2013 Mar 24. Review.

5.

Drug-resistant tuberculosis: time for visionary political leadership.

Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 Jun;13(6):529-39. doi: 10.1016/S1473-3099(13)70030-6. Epub 2013 Mar 24. Review.

6.

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.

McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O'Grady J, Pletschette M, Ditui L, Atun R, Zumla A.

J Infect Dis. 2012 May 15;205 Suppl 2:S147-58. doi: 10.1093/infdis/jir860. Epub 2012 Apr 10. Review.

PMID:
22496353
7.

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs.

Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R.

J Infect Dis. 2012 May 15;205 Suppl 2:S228-40. doi: 10.1093/infdis/jir858. Epub 2012 Apr 3.

PMID:
22476720
8.

Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M.

J Infect Dis. 2012 May 15;205 Suppl 2:S250-7. doi: 10.1093/infdis/jis041. Epub 2012 Mar 22.

PMID:
22448027
9.

Development and assessment of criteria to select projects for funding in the EU health programme.

Van den Broucke S, Dargent G, Pletschette M.

Eur J Public Health. 2012 Aug;22(4):598-601. doi: 10.1093/eurpub/ckr066. Epub 2011 Jun 20.

PMID:
21690183
10.

The European network of Biosafety-Level-4 laboratories: enhancing European preparedness for new health threats.

Nisii C, Castilletti C, Di Caro A, Capobianchi MR, Brown D, Lloyd G, Gunther S, Lundkvist A, Pletschette M, Ippolito G; Euronet-P4 Group.

Clin Microbiol Infect. 2009 Aug;15(8):720-6. doi: 10.1111/j.1469-0691.2009.02946.x. Review.

11.

Facing the threat of highly infectious diseases in Europe: the need for a networking approach.

Ippolito G, Fusco FM, Di Caro A, Nisii C, Pompa MG, Thinus G, Pletschette M, Capobianchi MR.

Clin Microbiol Infect. 2009 Aug;15(8):706-10. doi: 10.1111/j.1469-0691.2009.02876.x. Epub 2009 May 28. Review.

12.

Drug resistance and fitness in Mycobacterium tuberculosis infection.

Bottger EC, Pletschette M, Andersson D.

J Infect Dis. 2005 Mar 1;191(5):823-4; author reply 824. No abstract available.

13.

Editorial: Tuberculosis research: an end to neglect and negligence.

Pletschette M, Nair S.

Trop Med Int Health. 2004 Jul;9(7):817. No abstract available.

14.

Fitness cost of chromosomal drug resistance-conferring mutations.

Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Böttger EC.

Antimicrob Agents Chemother. 2002 May;46(5):1204-11.

15.

Fitness of antibiotic-resistant microorganisms and compensatory mutations.

Böttger EC, Springer B, Pletschette M, Sander P.

Nat Med. 1998 Dec;4(12):1343-4. No abstract available.

PMID:
9846553
16.

Tropical medicine in and out of the tropics.

De Bruycker M, Hagan P, Pletschette M.

Lancet. 1996 Apr 20;347(9008):1113. No abstract available.

PMID:
8602077
17.

Macrorestriction analysis of Pseudomonas aeruginosa in colonized burn patients.

Pradella S, Pletschette M, Mantey-Stiers F, Bautsch W.

Eur J Clin Microbiol Infect Dis. 1994 Feb;13(2):122-8.

PMID:
8013483
18.

Risk of bacteremia induced by transesophageal echocardiography: analysis of 100 consecutive procedures.

Nikutta P, Mantey-Stiers F, Becht I, Hausmann D, Mügge A, Böhm T, Pletschette M, Daniel WG.

J Am Soc Echocardiogr. 1992 Mar-Apr;5(2):168-72.

PMID:
1571172
19.

Opportunistic Capnocytophaga canimorsus infection.

Pletschette M, Köhl J, Kuipers J, Schmidt RE.

Lancet. 1992 Feb 1;339(8788):308. No abstract available.

PMID:
1346312
20.

Frequency of occurrence and characterization of catalase negative Campylobacter isolated from human feces in Vienna.

Hirschl AM, Pletschette M, Wolf D, Berger J, Diridl G, Rotter ML.

Zentralbl Bakteriol. 1990 Apr;272(4):547-53.

PMID:
2360973
21.

[Dental care of HIV carriers].

Ertl L, Wewalka G, Koller W, Banekovich M, Beck H, Pletschette M.

Z Stomatol. 1989 Sep;86(5 Suppl 4):1-12. German.

PMID:
2534685
22.

Infections following tickbites. Tick-borne encephalitis and Lyme borreliosis--a prospective epidemiological study from Tyrol.

Schmutzhard E, Stanek G, Pletschette M, Hirschl AM, Pallua A, Schmitzberger R, Schlögl R.

Infection. 1988 Sep-Oct;16(5):269-72.

PMID:
3215687
23.

[HIV infection and dentistry--basic aspects and prevention].

Ertl L, Pletschette M.

Z Stomatol. 1988 Sep;85(5):289-311. Review. German. No abstract available.

PMID:
3079096
24.

Comparison of different antigen preparations in an evaluation of the immune response to Campylobacter pylori.

Hirschl AM, Pletschette M, Hirschl MH, Berger J, Stanek G, Rotter ML.

Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):570-5.

PMID:
3141175
25.

[Measures against injuries with injection needles].

Pletschette M.

Osterr Krankenpflegez. 1988 Mar;41(3):82-3. German. No abstract available.

PMID:
3419820
26.

The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

Hirschl AM, Hentschel E, Schütze K, Nemec H, Pötzi R, Gangl A, Weiss W, Pletschette M, Stanek G, Rotter ML.

Scand J Gastroenterol Suppl. 1988;142:76-81.

PMID:
3166537
27.

European Lyme borreliosis.

Stanek G, Pletschette M, Flamm H, Hirschl AM, Aberer E, Kristoferitsch W, Schmutzhard E.

Ann N Y Acad Sci. 1988;539:274-82. Review. No abstract available.

PMID:
3056199
28.

[Correlations between various anatomo-pathologic criteria of cancer of the breast and the determination of hormonal receptors].

Lenzen B, Pletschette M, Capesius C.

Bull Soc Sci Med Grand Duche Luxemb. 1986;123(2):79-81. French. No abstract available.

PMID:
3802373
29.

A monoclonal antibody (GF 22.1) detecting different patterns of HLA class I cross-reactivities at different dilutions.

Sensi A, Baricordi OR, Melchiorri L, Balboni A, Pletschette M, Grappa MT, Mattiuz PL.

Tissue Antigens. 1985 Sep;26(3):204-9.

PMID:
3863262

Supplemental Content

Loading ...
Support Center